Search Results

MGC Pharmaceuticals Ltd, Rebrands as Argent BioPharma in Strategic Transformation Marking a significant milestone in its evolutionary journey, MGC Pharma has officially announced its rebranding to Argent BioPharma, pending approval from its shareholders.

MGC Pharmaceuticals Ltd., announces that its proprietary product CannEpil® is now available to patients in the UK by Named Patient Request.

Portfolio Expands to Include Non-Invasive Cardiorespiratory Diagnostic Systems CAIRE Inc., a subsidiary of NGK SPARK PLUG CO., LTD., will acquire St. Paul, Minnesota-based MGC Diagnostics Holdings, Inc. MGC designs, develops, manufactures, and markets non-invasive cardiorespiratory diagnostic systems, accessories, and consumables for the detection, classification, and management of cardiorespiratory disease.

MGC Diagnostics Corporation (“MGC”), a global medical technology company dedicated to cardiorespiratory health solutions, and a portfolio company of Altus Capital Partners, Inc. (“Altus”), announced today the acquisition of Lemon Medical, GmbH.

Selecting the ideal pharmaceutical label manufacturer requires careful consideration. This article compares leading companies, highlighting their strengths in regulatory compliance, material performance, serialization, innovation, and sustainability, to help you make an informed decision for your product’s safety and success.

Innovation drives speed in early phase drug development. ICON’s Accelerated Pharmaceutical Solutions integrate advanced formulation design, real-time dose flexibility, and cutting-edge CMC expertise to transform complexity into clarity. By uniting science, technology, and strategy, biotechs can move faster, smarter, and with confidence—turning obstacles into opportunities for breakthrough success.